V.V.V. & Sons Edible Oils Ltd. Vs. Meenakshi Overseas LLC

V.V.V. & Sons Edible Oils Ltd. Vs. Meenakshi Overseas LLC :05.06.2026:O.S.A. Nos. 63 & 64 of 2019, O.S.A. (CAD) No. 23 of 2022 and O.S.A. Nos. 139 & 140 of 2025:Madras HC:Hon'ble Judges: Justice P. Velmurugan and Justice K. Govindarajan Thilakavadi

The Court considered a dispute concerning trademark infringement and passing off involving the mark “IDHAYAM” used on products manufactured in India and exported to the United States. The case arose from allegations that the respondents had affixed the plaintiff’s registered mark on goods intended for export under arrangements with an entity holding registration of the same mark in the United States.

The principal question before the Court was whether the plaints and connected suit could be rejected at the threshold on grounds of absence of cause of action, suppression of facts, res judicata, non-joinder of parties and the existence of foreign trademark registrations.

After examining the material on record and the submissions of the parties, the Division Bench observed that while dealing with an application under Order VII Rule 11 CPC, the Court must confine itself to the averments in the plaint and cannot decide disputed questions of fact or rely upon the defendants’ defence. The Court held that issues relating to suppression, res judicata, Order II Rule 2 CPC, and the effect of foreign trademark registrations required a full-fledged trial, emphasizing that rejection of a plaint is permissible only when the bar is apparent from the plaint itself. The Court further observed that even if a party is necessary for effective adjudication, the proper course is to direct its impleadment rather than dismiss the suit.

Accordingly, the Court allowed all the appeals, set aside the orders rejecting the plaints and the judgment dismissing the suit, restored the suits to file, and directed that the connected matters be tried afresh on merits after affording the parties an opportunity to adduce evidence.

Disclaimer: Readers are advised not to treat this as a substitute for legal advice, as it is based on limited information and is intended solely for general informational purposes.

===

Only contents of the Plaint are to be seen while deciding Application under Order 7 Rule 11 CPC

Introduction

The judgment delivered by the Madras High Court in M/s V.V.V. & Sons Edible Oils Ltd. v. M/s Meenakshi Overseas LLC & Connected Matters is an important decision at the intersection of trademark law and civil procedure. The dispute revolved around the well-known “Idhayam” trademark and allegations that goods bearing the mark were being manufactured and exported from India for sale in the United States under arrangements involving entities claiming rights over the mark abroad.

The case raised significant questions regarding the territorial nature of trademark rights, the effect of foreign trademark registrations, the maintainability of infringement suits involving export activities, and, most importantly, the limited scope of rejection of plaints under Order VII Rule 11 of the Code of Civil Procedure, 1908.

The judgment is particularly relevant for trademark proprietors, exporters, manufacturers engaged in international trade, intellectual property practitioners, and litigants facing objections based on res judicata, suppression of facts, abuse of process, or non-joinder of parties. The decision reiterates that disputed questions of fact and law ordinarily cannot be decided at the threshold stage by rejecting a plaint and must instead be adjudicated through a full-fledged trial.

Factual and Procedural Background

M/s V.V.V. & Sons Edible Oils Limited is a well-known Indian manufacturer and marketer of sesame oil sold under the trademark “Idhayam.” The company asserted that the mark had been registered in India since 1986 and had acquired considerable goodwill and reputation both domestically and internationally.

According to the plaintiff, M/s Meenakshi Overseas LLC, a company based in the United States, had obtained registration of the mark “Idhayam” in the United States. The plaintiff alleged that this registration had been obtained through misrepresentation and that the foreign entity had also registered trademarks associated with other well-known Indian brands. The plaintiff further claimed that Indian entities, including Shivaraja Impex Company and Damodar Foods, were affixing the mark “Idhayam” or similar marks on goods in India and exporting them to the United States.

Several proceedings arose from these allegations.

In C.S. No. 726 of 2017, the plaintiff sought relief against Meenakshi Overseas LLC, Shivaraja Impex Company, and Damodar Foods. The plaint was subsequently rejected under Order VII Rule 11 CPC on the ground that it did not disclose a valid cause of action and that the plaintiff had suppressed material facts concerning earlier proceedings in the United States.

In C.S. No. 434 of 2017, Damodar Foods was sued for alleged infringement and passing off. Following a full trial, the suit was dismissed. The Single Judge held that the suit suffered from non-joinder of Meenakshi Overseas LLC, which held the U.S. registration, and further concluded that the goods were intended exclusively for export and that the plaintiff could not restrain such activities in the circumstances of the case.

The plaintiff also instituted C.S. No. 987 of 2017 and C.S. No. 235 of 2020 seeking injunctions and damages. These suits too were rejected under Order VII Rule 11 CPC on the grounds of res judicata and Order II Rule 2 CPC, the courts holding that the plaintiff was attempting to re-litigate matters already adjudicated.

Aggrieved by these orders and judgments, the plaintiff filed a batch of appeals, namely O.S.A. Nos. 63 and 64 of 2019, O.S.A. (CAD) No. 23 of 2022, and O.S.A. Nos. 139 and 140 of 2025 before the Division Bench of the Madras High Court.

Dispute Before the Court

The central issue before the Division Bench was whether the various orders rejecting the plaints and dismissing the suit were legally sustainable.

The plaintiff argued that its registered trademark rights under Indian law were independent of any proceedings or registrations in the United States. It contended that the defendants were affixing the disputed mark in India and exporting goods bearing that mark, thereby committing infringement within India. The plaintiff further argued that foreign litigation could not extinguish rights conferred by Indian trademark registrations and that each export transaction constituted a fresh cause of action.

The defendants, on the other hand, maintained that the plaintiff had already challenged the U.S. registration abroad and failed. They contended that the Indian proceedings amounted to suppression of material facts, re-litigation, abuse of process, and were barred by res judicata and Order II Rule 2 CPC. They also argued that Meenakshi Overseas LLC was a necessary party and that exports undertaken under a valid foreign trademark registration could not be restrained.

Thus, the Court was required to determine whether these objections justified rejection of the plaints at the threshold stage and whether dismissal of the suit on grounds of non-joinder and related procedural objections was legally justified.

Reasoning and Analysis of the Court

The Division Bench undertook a detailed examination of the principles governing Order VII Rule 11 CPC.

The Court reiterated the settled principle that while considering an application under Order VII Rule 11 CPC, the Court must confine itself to the averments contained in the plaint and the documents relied upon by the plaintiff. The defence set up by the defendant cannot ordinarily be considered at that stage.

Examining the plaint in C.S. No. 726 of 2017, the Court found that it clearly contained material facts constituting a cause of action. The plaintiff had specifically alleged that Indian entities were affixing the impugned trademark within India and exporting goods bearing that mark. These allegations, if proved, could potentially give rise to a valid claim under Indian trademark law. Consequently, the Court held that rejection of the plaint on the ground of absence of cause of action was unjustified.

The Court further observed that the foreign proceedings in the United States were not, by themselves, determinative of the plaintiff’s rights under Indian trademark law. The suits before the Indian courts were not directed at restraining sales in the United States but were based upon alleged acts of affixation and export occurring within India. Whether those acts amounted to infringement was a matter requiring evidence and trial.

The Division Bench also considered the allegations of suppression of material facts and abuse of process. Referring to the Supreme Court’s decision in K.K. Modi v. K.N. Modi (1998) 3 SCC 573, which deals with abuse of judicial process and re-litigation, the Court held that the precedent could not be mechanically applied. Whether suppression had occurred and whether it was sufficient to non-suit the plaintiff were issues requiring proper adjudication and could not ordinarily be conclusively determined at the Order VII Rule 11 stage.

With respect to the rejection of the plaints in C.S. Nos. 987 of 2017 and 235 of 2020 on grounds of res judicata and Order II Rule 2 CPC, the Court found that the earlier suit relied upon for invoking these bars had not been finally decided when the later suits were instituted. Since final adjudication is an essential requirement for attracting Section 11 CPC, the bar of res judicata was not apparent from the plaint itself.

The Court referred to Section 10 CPC, which deals with stay of suits where substantially similar issues are pending in an earlier suit. It noted that questions regarding identity of causes of action, continuing wrongs, and applicability of Order II Rule 2 CPC involved mixed questions of fact and law that could not be decided summarily without evidence.

Another important aspect of the judgment concerned non-joinder of parties. In C.S. No. 434 of 2017, the suit had been dismissed largely because Meenakshi Overseas LLC had not been impleaded. The Division Bench referred to Order I Rule 9 CPC and Order I Rule 10(2) CPC and held that even if Meenakshi Overseas LLC was a necessary party, the appropriate course was to direct its impleadment rather than dismiss the suit outright.

The Court emphasized that the key issues concerning the effect of foreign trademark registrations, alleged infringement through export activities, and the interpretation of Sections 29(6), 30(2)(b), and 56 of the Trade Marks Act, 1999 were common to all the connected suits. Since these issues had not been comprehensively adjudicated with participation of all necessary parties, the interests of justice required a fresh and consolidated examination.

The Court also discussed and considered several authorities cited by the parties, including Crompton Greaves Ltd. v. Salzer Electronics Ltd.  [2011 (6) CTC 157] , Mahendra & Mahendra Paper Mills Ltd. v. Mahindra & Mahindra Ltd. [ AIR(2002)SC117 ], Cadila Pharmaceuticals Ltd. v. Madley Laboratories [(2011)SCC OnLine Bom 484], Kamala v. K.T. Eshwara Sa, Alpana Gupta v. APG Towers Pvt. Ltd. [AIR(2008) SC 3174], and Kum. Geetha v. Nanjundaswamy [AIR(2023) SC 5516]. However, the Court primarily focused on the procedural question of whether the disputes could be terminated at the threshold stage and concluded that a full trial was necessary.

Final Decision of the Court

The Division Bench allowed all the appeals.

The orders rejecting the plaint in C.S. No. 726 of 2017 were set aside and the suit was restored for fresh consideration on merits.The orders rejecting the plaints in C.S. No. 987 of 2017 and C.S. No. 235 of 2020 were also set aside, and those suits were restored to the file of the Single Judge for trial and adjudication on merits.The judgment and decree dated 23 August 2021 in C.S. No. 434 of 2017 were likewise set aside and the matter was remanded for fresh adjudication.The Court granted liberty to the plaintiff to implead Meenakshi Overseas LLC in the connected suits .

Point of Law Settled

The judgment reinforces several important legal principles:

A plaint can be rejected under Order VII Rule 11 CPC only when the absence of a cause of action or the legal bar to the suit is apparent from the plaint itself. Courts cannot evaluate disputed facts or rely on the defendant’s version while exercising powers under Order VII Rule 11 CPC.

Questions relating to suppression of facts, abuse of process, res judicata, continuing cause of action, and applicability of Order II Rule 2 CPC often involve mixed questions of fact and law and ordinarily require evidence before they can be conclusively decided.

Where a court considers a party necessary for effective adjudication, the preferred course is ordinarily to direct impleadment under Order I Rule 10 CPC rather than dismissing the suit altogether.

The judgment also underscores that disputes concerning alleged trademark infringement through activities occurring within India cannot be summarily dismissed merely because related trademark proceedings or registrations exist in a foreign jurisdiction.

Title of the Case:  V.V.V. & Sons Edible Oils Ltd. Vs Meenakshi Overseas LLC & Ors. 

Date of Judgment/Order: 05 June 2026

Case Number: O.S.A. No. 63 of 2019, O.S.A. No. 64 of 2019, O.S.A. (CAD) No. 23 of 2022, O.S.A. No. 139 of 2025 and O.S.A. No. 140 of 2025

Name of Court: High Court of Judicature at Madras

Name of Hon'ble Judge: Hon'ble Mr. Justice P. Velmurugan and Hon'ble Mrs. Justice K. Govindarajan Thilakavadi

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Suggested SEO Titles:

1. Madras High Court on Order VII Rule 11 CPC in Trademark Infringement Suits
2. Idhayam Trademark Dispute: Madras High Court Restores Rejected Suits
3. Foreign Trademark Registration vs Indian Trademark Rights: Key Madras High Court Ruling
4. Res Judicata and Trademark Litigation: Analysis of V.V.V. & Sons Edible Oils Judgment
5. When Can a Plaint Be Rejected? Madras High Court Clarifies Order VII Rule 11 CPC
6. Export of Goods and Trademark Infringement in India: Important 2026 Decision
7. Non-Joinder of Necessary Party in Trademark Suits: Madras High Court Explains Law
8. Trademark Rights and Export Activities: Legal Analysis of Idhayam Case
9. Scope of Order VII Rule 11 CPC in Intellectual Property Litigation
10. Madras High Court Remands Multiple Trademark Suits for Fresh Trial
11. Indian Trademark Rights Despite Foreign Registrations: Judicial Perspective
12. Comprehensive Analysis of V.V.V. & Sons Edible Oils Ltd. v. Meenakshi Overseas LLC

Suggested SEO Tags:

Trademark Infringement, Trade Marks Act 1999, Order VII Rule 11 CPC, Rejection of Plaint, Res Judicata, Order II Rule 2 CPC, Trademark Litigation India, Export and Trademark Law, Idhayam Trademark, Madras High Court Judgment, Intellectual Property Law, Passing Off, Trademark Registration, Foreign Trademark Registration, Cause of Action, Non Joinder of Necessary Party, Order I Rule 10 CPC, Order I Rule 9 CPC, Civil Procedure Code, Trademark Enforcement, Export Goods Trademark Dispute, Indian Trademark Rights, Commercial Litigation, IP Litigation India, Trademark Appeals, Damodar Foods Case, Meenakshi Overseas LLC, VVV Sons Edible Oils, AdvocateAjayAmitabhSuman, IPAdjutor

Headnote of the Judgment:

The plaintiff, proprietor of the well-known “Idhayam” trademark in India, filed multiple suits alleging that the defendants were affixing the mark in India and exporting goods to the United States, thereby infringing its trademark rights. Certain suits were dismissed or had their plaints rejected under Order VII Rule 11 CPC on grounds including absence of cause of action, suppression of material facts, res judicata, Order II Rule 2 CPC, and non-joinder of a necessary party. The Madras High Court held that while deciding an application under Order VII Rule 11 CPC, the Court must confine itself to the plaint and cannot adjudicate disputed factual issues or rely upon the defendant’s defence. The Court further held that questions relating to suppression, res judicata, continuing cause of action, and Order II Rule 2 CPC involved mixed questions of fact and law requiring trial. It also observed that if a party is necessary for adjudication, the proper course is generally to direct impleadment rather than dismiss the suit. Consequently, all appeals were allowed, the orders rejecting the plaints and the judgment dismissing the suit were set aside, and the matters were remanded for fresh adjudication on merits.

Anil Srichand Kundnani Vs Pruthvi Ishwar

Anil Srichand Kundnani Vs Pruthvi Ishwar Patel:08.06.2026:Commercial IP Suit No. 434 of 2025:2026:BHC-OS:12554:Bombay HC:Hon'ble Judge Sharmila U. Deshmukh

The Court considered a dispute concerning copyright infringement and passing off in relation to the artistic label and trade dress of packaged tea products. The case arose from allegations that the defendants had adopted the label mark “UTSAHA”, which was alleged to be a slavish reproduction of the plaintiff’s “UMANG” label and artwork.

The principal question before the Court was whether the defendants’ label and packaging infringed the plaintiff’s copyright in its artistic work and amounted to passing off, notwithstanding objections regarding the validity of the plaintiff’s copyright registration and trademark applications.

After examining the material on record and the submissions of the parties, Justice Sharmila U. Deshmukh observed that the rival labels were deceptively similar in their overall get-up, colour scheme, arrangement of features and stylized presentation, and that the defendants had failed to establish independent creation of the impugned artwork. The Court held that copyright protection extends to the expression of an idea embodied in the artistic work and that substantial similarity, judged from the perspective of a lay observer, constitutes infringement. The Court further emphasized that the proviso to Section 45(1) of the Copyright Act is concerned with similarity of artistic works and not with conflicting word marks.

Accordingly, the Court allowed the interim application and confirmed the ad-interim injunction, restraining the defendants from infringing the plaintiff’s original artwork and from passing off their products as those of the plaintiff.

Disclaimer: Readers are advised not to treat this as a substitute for legal advice, as it is based on limited information and is intended solely for general informational purposes.

====

Slavish Reproduction of Packaging Artwork and Passing Off

Bombay High Court Protects “UMANG” Tea Packaging: Copyright and Passing Off Action Succeeds Against Alleged Imitation of Trade Dress

Introduction

The protection of packaging, labels, and overall trade dress has become increasingly important in modern commerce, particularly in the food and consumer goods industry where visual appearance significantly influences consumer choice. The decision of the Bombay High Court in Anil Srichand Kundnani, Proprietor of Bhagyalaxmi Tea Centre v. Pruthvi Ishwar Patel, Proprietor of Maa Bahucharaji Sales & Anr. is an important ruling dealing with copyright in artistic labels and the law of passing off.

The case involved allegations that the defendants had copied the overall packaging and artistic features of the plaintiff's well-known “UMANG” tea products and marketed their own tea under the label “UTSAHA”. Apart from issues relating to copyright infringement and passing off, the dispute also raised interesting questions concerning the interplay between the Copyright Act, 1957 and the Trade Marks Act, 1999, the effect of refusal of trademark applications, ownership of artistic works, and the relevance of copyright registrations obtained by rival parties.

The judgment is significant for businesses dealing with packaged goods, intellectual property practitioners, and brand owners because it reiterates that copyright protection extends not merely to ideas but to the manner in which those ideas are expressed through distinctive artistic arrangements and trade dress.

Factual and Procedural Background

The plaintiff, proprietor of Bhagyalaxmi Tea Centre, claimed to have adopted the mark “UMANG” in 2009 for manufacturing and marketing premium packaged tea and related products. Over the years, several trademark registrations and applications relating to “UMANG”, “UMANGAM”, and associated device marks were obtained. The plaintiff also secured copyright registration in respect of one of the artistic labels.

According to the plaintiff, the label and artwork had been conceived and created by him and had acquired substantial goodwill through continuous use and extensive sales. Sales turnover for the period from 2021 to 2024 was stated to be approximately ₹19.58 crores.

In January 2024, the plaintiff allegedly discovered tea products marketed under the label “UTSAHA”. A complaint was lodged and a cease-and-desist notice dated 15 February 2024 was issued to the defendants. Investigation revealed that the first defendant had applied for registration of the “UTSAHA” device mark on 27 June 2023.

Commercial IP Suit No. 434 of 2025 was instituted before the Commercial Division of the Bombay High Court seeking reliefs for copyright infringement and passing off. On 14 June 2024, the Court granted ex parte ad interim protection restraining the defendants from using the impugned label and directed disclosure by the defendants.

The defendants thereafter filed affidavits opposing continuation of the interim order. They alleged suppression of material facts by the plaintiff and contended that the plaintiff's copyright registration itself was invalid.

Dispute Before the Court

The principal issue before the Court was whether the defendants had copied the plaintiff's original artistic work embodied in the “UMANG” tea label and whether such copying amounted to copyright infringement and passing off.

The plaintiff contended that the impugned “UTSAHA” packaging was a slavish reproduction of its own label and that the overall colour combination, arrangement of features, depiction of tea cups and cardamom, stylized fonts and trade dress had been copied.

The defendants argued that the plaintiff had concealed material facts, including refusal of an earlier trademark application. They further submitted that the plaintiff was not the owner of copyright because the registration certificate mentioned another person as the author of the artistic work and no assignment deed had been produced.

It was also argued that the plaintiff's copyright registration was invalid in view of Section 45 of the Copyright Act, 1957. According to the defendants, the common features such as green colour, tea cups and cardamom were generic elements ordinarily used in tea packaging and therefore no monopoly could be claimed over them.

Reasoning and Analysis of the Court

Upon comparing the rival products, the Court found striking similarities between the competing labels. It observed that the background consisting of shaded green colour, the bed of cardamoms, placement of the tea cup, stylized font, colour arrangement and positioning of various elements were almost identical. The Court concluded that the dispute was not confined merely to common features such as tea cups or cardamom but involved copying of the entire trade dress.

The Court held that copyright protects the expression of an idea and not the idea itself. While the concept of depicting tea and cardamom may be common, the particular manner in which those elements had been arranged and expressed constituted protectable artistic expression.

An important circumstance noticed by the Court was that the defendants themselves had opposed registration of the plaintiff's “UMANGAM” label by alleging deceptive similarity with their own label. According to the Court, such opposition amounted to an implicit admission that the rival artworks were deceptively similar.

The defendants had argued that the copyright certificate showed a third party as the author and no assignment deed had been produced. The Court rejected this argument on the ground that such a defence had not been pleaded in the affidavits and could not be raised for the first time during oral arguments. Since ownership pleaded by the plaintiff had never been specifically denied, the defendants could not advance an entirely new case at the hearing stage.

The Court referred to Rule 70(3) of the Copyright Rules, 2013, which permits an owner of copyright to seek registration upon furnishing a No Objection Certificate from the author. Since registration had been granted, the Court presumed, at the interlocutory stage, that all necessary documents had been produced before the Registrar.

Interestingly, the Court noticed that the defendants' own copyright certificate also showed a third party as author and no assignment deed had been placed on record. Therefore, the same objection raised against the plaintiff would equally affect the defendants.

The Court then examined Section 45(1) of the Copyright Act, 1957, which requires a certificate from the Registrar of Trade Marks certifying that no identical or deceptively similar trademark application has been made by a third party. The Court held that the purpose of the proviso is to avoid conflict between competing claims over identical artistic works.

According to the Court, the expression used in Section 45 focuses on similarity of artistic works and applications made by third parties. Since the trademark applications in question had been filed by the plaintiff itself and the objection raised by the Trade Marks Registry concerned the word mark “UMANG” under Section 11(1) of the Trade Marks Act, 1999, the copyright registration could not be regarded as invalid.

The Court emphasized that copyright infringement is determined by applying the substantial similarity test. A lay observer examining both products would immediately notice the resemblance between them. The Court held that the defendants had failed to explain how such extensive similarities had arisen.

The Court also observed that the defendants had obtained copyright registration only in respect of a cropped version of the artwork and not for the entire packaging actually used by them. Several features appearing on the actual packaging and resembling the plaintiff's artwork were absent from the registered artwork. The absence of any explanation for this discrepancy persuaded the Court to infer dishonest conduct.

The Court further held that the plaintiff had established goodwill and reputation in the market since 2009 and had demonstrated substantial sales figures. Consequently, use of deceptively similar artwork by the defendants constituted misrepresentation likely to cause damage to the plaintiff's business.

While considering authorities cited by the parties, the Court referred to Sanjay Soya Private Limited v. Narayani Trading Company, IA (L) No. 5011 of 2020 decided on 9 March 2021; Hiralal Prabhudas v. Ganesh Trading Co., 1983 SCC OnLine Bom 284; ITC Limited v. Britannia Industries Limited, 2023 SCC OnLine Mad 6972; Colgate Palmolive Company v. Anchor Health and Beauty Care Pvt. Ltd., 2003 SCC OnLine Del 1005; Xotik Frujus Pvt. Ltd. v. Bubalus Beverages; Marico Ltd. v. Zee Hygiene Products Pvt. Ltd.IA(L) No. 24055 of 2021 decided on 25th November, 2022 by Bombay High Court.; Hugo Boss Trademark Management GmbH v. Sandeep Arora, 2023:DHC:8930; Jagdish Gopal Kamath v. Lime & Chilli Hospitality Services Pvt. Ltd., MANU/MH/0384/2015; Corn Products Refining Co. v. Shangrila Food Products Ltd., AIR 1960 SC 142 and Hygienic Research Institute Pvt. Ltd. v. Chandan and Shah Trading LLP, (2025) 1 HCC (Bom) 25.

The defendants had relied upon Abdul Cadur Allibhoy v. Mahomedally Hyderally, Vol. III Bombay Law Reporter 218. The Court held that the principles laid down therein were not applicable to the facts of the present case.

Final Decision of the Court

The Bombay High Court held that the plaintiff had established a strong prima facie case of copyright infringement and passing off. It found that the impugned “UTSAHA” label constituted a substantial and slavish reproduction of the plaintiff's original “UMANG” artwork.

The Court confirmed the ad interim injunction granted on 14 June 2024 and made the interim application absolute in terms of prayer clauses (a), (b) and (c). Consequently, the defendants were restrained from using the impugned label and from infringing the plaintiff's artistic work and passing off their products as those of the plaintiff.

Point of Law Settled

The judgment reiterates that copyright protects the expression of an idea rather than the underlying idea itself. Common elements may individually be incapable of protection, but their distinctive arrangement and overall trade dress can constitute protectable artistic expression.

The decision also clarifies that refusal of a trademark application does not automatically invalidate copyright registration under Section 45 of the Copyright Act, 1957. The proviso to Section 45 is concerned with conflicting claims by third parties and not with applications filed by the same applicant.

The ruling further emphasizes the importance of the substantial similarity test and the perspective of an ordinary observer in determining copyright infringement. It reinforces that dishonest imitation of overall packaging and trade dress can give rise to both copyright infringement and passing off even where individual features are commonly used in the trade.

Case Details

Title of the Case: Anil Srichand Kundnani v. Pruthvi Ishwar Patel & Anr.

Date of Judgment/Order: 08 June 2026

Case Number: Interim Application (L) No. 13908 of 2024 in Commercial IP Suit No. 434 of 2025, along with Interim Application No. 5393 of 2025

Neutral Citation: 2026:BHC-OS:12554

Name of Court: High Court of Judicature at Bombay

Name of Hon'ble Judge: Justice Sharmila U. Deshmukh

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Suggested SEO Titles

1. Bombay High Court Grants Injunction in UMANG vs UTSAHA Tea Packaging Copyright Dispute

2. Copyright Protection of Product Packaging: Analysis of Anil Srichand Kundnani v. Pruthvi Ishwar Patel

3. Trade Dress and Artistic Work Infringement in Tea Packaging: Bombay High Court Decision 2026

4. UMANG Label Mark Case: Court Restrains Use of Deceptively Similar UTSAHA Packaging

5. Copyright in Commercial Labels and Packaging: Key Takeaways from 2026:BHC-OS:12554

6. Bombay High Court on Slavish Reproduction of Packaging Artwork and Passing Off

7. Interplay Between Trademark and Copyright Law in Label Marks: UMANG Case Analysis

8. Copyright Registration of Artistic Labels and Section 45 of the Copyright Act Explained

9. Passing Off Through Imitation of Trade Dress: Bombay High Court's Ruling in UMANG Tea Case

10. Deceptive Similarity in Product Packaging: A Landmark Commercial IP Decision of 2026

11. Copyright Infringement in Tea Packaging Design: Judicial Protection of Original Artistic Works

12. Bombay High Court Clarifies Scope of Section 45 Copyright Act in Artistic Label Registrations

Suggested SEO Tags

copyright infringement, artistic work copyright, label mark infringement, trade dress infringement, passing off action, tea packaging dispute, UMANG trademark, UTSAHA trademark, copyright registration, trademark and copyright overlap, Section 45 Copyright Act, Copyright Rules 2013, deceptive similarity, slavish reproduction, commercial IP suit, Bombay High Court IP cases, packaging artwork protection, copyright in labels, trademark litigation India, intellectual property law India, trade dress protection India, copyright ownership dispute, interim injunction IP case, commercial division Bombay High Court, product packaging copyright, copyright and trademark interplay, passing off jurisprudence, artistic label protection, AdvocateAjayAmitabhSuman, IPAdjutor

Headnote of the Judgment

The Plaintiff, proprietor of the “UMANG” tea brand, instituted a suit alleging copyright infringement and passing off against the Defendants for using the “UTSAHA” tea packaging, which allegedly copied the Plaintiff’s artistic label and trade dress. The Defendants challenged the Plaintiff’s copyright ownership and validity of registration under Section 45 of the Copyright Act, 1957. The Bombay High Court held that the Defendant’s packaging was a slavish reproduction of the Plaintiff’s original artistic work, exhibiting substantial similarity in colour scheme, arrangement, design elements, and overall trade dress. The Court further held that refusal of a trademark application based on an identical word mark did not invalidate copyright registration in the artistic work. Finding a strong prima facie case of copyright infringement and passing off, the Court confirmed the ad-interim injunction and restrained the Defendants from using the impugned artwork and label mark.

=====

Alkem Laboratories Ltd. Vs. Numen Pharma Private Limited

Alkem Laboratories Ltd. Vs. Numen Pharma Private Limited:08 June 2026 :Commercial IP Suit No. 679 of 2025 :BombHC: Hon'ble Judge: Justice Sharmila U. Deshmukh

The Court considered a dispute concerning trademark infringement and passing off in relation to pharmaceutical products marketed under the marks “ALCIPRO” and “ACIPROX”. The case arose from allegations that the defendant had adopted the mark “ACIPROX”, which the plaintiff contended was deceptively similar to its long-standing registered trademark “ALCIPRO”.

The principal question before the Court was whether the defendant’s mark “ACIPROX” was phonetically similar to the plaintiff’s registered mark “ALCIPRO” so as to give rise to a likelihood of confusion, particularly in the case of medicinal preparations.

After examining the material on record and the submissions of the parties Court  observed that the rival marks must be compared as a whole and not dissected syllable by syllable. The Court found that “ALCIPRO” and “ACIPROX” were phonetically similar and that even a bare possibility of confusion in relation to medicinal products must be prevented. The Court held that a registered proprietor is entitled to restrain the use of an identical or deceptively similar mark, emphasizing that differences in packaging, colour schemes, or the fact that the products are Schedule ‘H’ drugs do not eliminate the likelihood of confusion.

Accordingly, the Court allowed the interim application and granted an injunction restraining the defendant from manufacturing, selling, marketing, or otherwise using the mark “ACIPROX” or any other mark deceptively similar to the plaintiff’s registered trademark “ALCIPRO” pending disposal of the suit.

Disclaimer: Readers are advised not to treat this as a substitute for legal advice, as it is based on limited information and is intended solely for general informational purposes.

===

Differences in packaging, house marks and prescription-based sale in relation to medicinal product and Trademark Confusion

---

Alkem Laboratories Ltd. v. Numen Pharma Private Limited: Bombay High Court Protects Pharmaceutical Trademark “ALCIPRO” Against Use of “ACIPROX”

Introduction

Trademark disputes involving medicinal products are treated with exceptional seriousness because even a minor possibility of confusion between two pharmaceutical products can have grave consequences for public health. The Bombay High Court's decision in Alkem Laboratories Ltd. v. Numen Pharma Private Limited reiterates the settled principle that in the case of medicines, courts apply a stricter standard and seek to eliminate even the possibility of confusion.

The dispute involved the registered trademark "ALCIPRO", used by Alkem Laboratories for several decades, and the mark "ACIPROX" adopted by a comparatively recent entrant in the pharmaceutical market. The case raised important questions concerning phonetic similarity, the anti-dissection rule, the effect of International Non-Proprietary Names (INN), common-to-trade arguments, and the degree of protection available to medicinal trademarks.

The judgment is of considerable importance to pharmaceutical companies, trademark owners, medical practitioners, and intellectual property lawyers, as it reinforces the principle that public safety outweighs commercial convenience when deceptively similar medicinal marks are involved.

Factual and Procedural Background

Alkem Laboratories Ltd., a well-known pharmaceutical company, adopted the trademark "ALCIPRO" in 1990 and obtained registration in Class 5 on 4 April 1990. Subsequently, on 28 September 1998, it secured registration for the variant mark "ALCIPRO-TN". The products bearing the "ALCIPRO" mark contain Ciprofloxacin and are used for the treatment of bacterial infections, urinary tract infections, throat infections, skin infections and respiratory infections.

Over the years, Alkem introduced several variants of the "ALCIPRO" range and established extensive goodwill and reputation in the market. The plaintiff produced evidence of sales and promotional activities and demonstrated long and continuous use of the mark.

In December 2023, Alkem came across an application advertised in the Trade Marks Journal for registration of the mark "ACIPROX", filed by Numen Pharma Private Limited on 16 January 2023 on a proposed-to-be-used basis. Alkem filed an opposition to the application. In response, the defendant claimed use of the impugned mark since 2023.

Alkem instituted Commercial IP Suit No. 679 of 2025 before the Commercial Division of the Bombay High Court seeking reliefs for trademark infringement and passing off. On 8 October 2025, the Court granted ad-interim protection in favour of Alkem.

Numen Pharma filed an affidavit in reply dated 22 November 2025 and an additional affidavit dated 19 March 2026 opposing the interim application. After hearing the parties, the Court reserved the matter on 24 April 2026 and pronounced its order on 8 June 2026.

Dispute Before the Court

The principal question before the Court was whether the mark "ACIPROX" used by the defendant was deceptively similar to the plaintiff's registered mark "ALCIPRO" and whether such use amounted to infringement and passing off.

Alkem contended that "ALCIPRO" was an invented and distinctive mark which had acquired substantial reputation since 1990. It argued that the defendant's mark differed merely by deletion of the letter "L" and addition of the letter "X", creating a high likelihood of confusion. Since the products involved medicinal preparations with different compositions and therapeutic uses, even a slight possibility of confusion could produce dangerous consequences.

Numen Pharma argued that the expression "CIPRO" was descriptive and derived from the molecule Ciprofloxacin, which forms part of the International Non-Proprietary Name system. According to the defendant, the plaintiff could not claim monopoly over such a generic component. It further contended that the rival marks were visually and phonetically distinct, the packaging and trade dress were different, and the medicines were Schedule H drugs sold only on prescription, thereby eliminating the possibility of confusion.

The defendant also relied upon the existence of numerous trademarks containing the expression "CIPRO" and asserted that the impugned mark had been honestly adopted after conducting a search of the trademark registry.

Reasoning and Analysis of the Court

The Court observed that the plaintiff's product and the defendant's product contained entirely different active ingredients and were intended for treatment of different ailments. Consequently, substitution of one medicine for the other could have hazardous consequences.

The Court emphasized that in cases involving medicinal products, even the slightest possibility of confusion must be prevented. It noted that the dispute was essentially between "ALCIPRO" and "ACIPROX", where the defendant had merely omitted the letter "L" and added the letter "X". The Court rejected the defendant's attempt to compare the marks syllable by syllable and reaffirmed the anti-dissection rule, according to which marks must be considered as a whole.

The Court relied heavily upon the Division Bench decision in Sun Pharmaceutical Industries Ltd. v. Meghmani Lifesciences Ltd. & Anr., Comm. Order 08.04.2026 in Appeal (L) No.42382 of 2025, where the rival marks "RACIRAFT" and "ESIRAFT" were examined. The Division Bench had held that dissecting marks into individual syllables was impermissible and that phonetic similarity should be assessed by considering the marks in their entirety.

Applying this principle, the Court held that "ALCIPRO" and "ACIPROX" were phonetically similar. It observed that hurried pronunciation or mispronunciation could easily create confusion and that the terminal letter "X" was insufficient to distinguish the marks.

The Court reiterated that the possibility of confusion assumes greater significance in a multilingual country like India, where varying levels of literacy and pronunciation exist.

The Court relied extensively upon the landmark decision of the Supreme Court in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, which laid down that even prescription drugs are susceptible to confusion and that a higher standard of care is required for medicinal products. The Supreme Court had emphasized that doctors and pharmacists are not immune from mistakes and that linguistic diversity and varying standards of healthcare infrastructure necessitate strict measures against deceptively similar medicinal marks.

Reference was also made to Milmet Oftho Industries v. Allergan Inc., (2004) 12 SCC 624, where the Supreme Court stressed that confusion involving medicinal products demands exacting judicial scrutiny because the consequences may be far more serious than those involving ordinary consumer goods.

The Court rejected the defendant's argument that the medicines were Schedule H drugs and therefore confusion was unlikely. It held that prescriptions are often handwritten or communicated orally and mistakes are possible even among professionals.

On the issue of International Non-Proprietary Names, the Court held that the plaintiff was not seeking monopoly over "Ciprofloxacin" itself. The exclusivity claimed was in the distinctive combination embodied in the mark "ALCIPRO". The plaintiff's registration dated back to 1990 under the Trade and Merchandise Marks Act, 1958, whereas the notification concerning INNs under Section 13 of the Trade Marks Act, 1999 came much later. Therefore, Section 13 did not invalidate or diminish the plaintiff's rights.

The Court also referred to Lupin Ltd. v. Eris Lifesciences (P) Ltd., 2015 SCC OnLine Bom 6807, observing that the defendant had not challenged the validity of the plaintiff's registration within the narrow window recognised in that decision. Under Section 31 of the Trade Marks Act, registration constitutes prima facie evidence of validity.

The defendant's reliance upon the existence of numerous marks containing "CIPRO" was rejected. The Court observed that mere entries on the register are insufficient to establish that a mark has become common to the trade. It relied on Jagdish Gopal Kamath v. Lime & Chilli Hospitality Services Pvt. Ltd., 2015 SCC OnLine Bom 531, where it had been held that extensive and widespread use must be demonstrated before a mark can be treated as common to the trade.

With respect to passing off, the Court examined Section 27(2) of the Trade Marks Act, 1999 and relied upon Laxmikant V. Patel v. Chetanbhai Shah, (2002) 3 SCC 65, where the Supreme Court held that likelihood of damage is sufficient and proof of actual fraud or actual damage is unnecessary.

The Court also relied upon Satyam Infoway Ltd. v. Siffynet Solutions (P) Ltd., (2004) 6 SCC 145, which explained that misrepresentation in passing off does not require proof of mala fide intention.

The Court distinguished the authorities cited by the defendant. It held that Sun Pharmaceutical Laboratories Ltd. v. Hetero Healthcare Ltd., 2022 SCC OnLine Del 2580, involved marks derived from the same generic drug and therefore turned on entirely different facts. Similarly, Aristo Pharmaceutical Pvt. Ltd. v. Healing Pharma India Pvt. Ltd., 2025 SCC OnLine Bom 4693, concerned an undisguised clipped version of a generic term without any distinctive addition. The Court found those decisions inapplicable.

The Supreme Court's decision in F. Hoffmann-La Roche & Co. Ltd. v. Geoffrey Manners & Co. Pvt. Ltd., (1969) 2 SCC 716, was also distinguished on facts, although the principle that marks must be compared as a whole was accepted.

After examining the evidence, the Court concluded that the plaintiff had established goodwill and reputation built over decades and that the defendant, being incorporated only in 2023, was a late entrant. The balance of convenience clearly favoured the plaintiff.

Final Decision of the Court

The Bombay High Court held that the plaintiff had established a strong prima facie case for trademark infringement and passing off.

The Court found that "ACIPROX" was deceptively similar to "ALCIPRO" and that continued use of the impugned mark was likely to create confusion with potentially serious consequences because the medicines treated different ailments.

Accordingly, the interim application was allowed and the earlier ad-interim protection was confirmed. The defendant, along with its directors, employees, distributors, agents and all persons acting on its behalf, was restrained from manufacturing, selling, advertising, marketing or otherwise using the mark "ACIPROX" or any other mark identical or deceptively similar to "ALCIPRO" pending disposal of the suit. The Court also granted relief in respect of passing off.

Point of Law Settled

The judgment reaffirms that in pharmaceutical trademark disputes, the test is not actual confusion but the possibility of confusion. Courts are required to apply a stricter standard because mistakes in dispensing medicines may endanger public health.

The decision reiterates the anti-dissection rule and confirms that rival marks must be compared as a whole rather than syllable by syllable. It further clarifies that differences in packaging, colour schemes, house marks or the fact that medicines are prescription drugs do not eliminate the likelihood of confusion.

The judgment also emphasizes that mere existence of similar marks on the register does not establish that a mark is common to the trade unless extensive and widespread use is proved. It additionally reinforces the evidentiary value of registration under Section 31 of the Trade Marks Act, 1999 and underscores that goodwill acquired through long-standing use will receive strong judicial protection against late entrants.

---

Case Details:

Title of the Case: Alkem Laboratories Ltd. v. Numen Pharma Private Limited

Date of Judgment/Order: 8 June 2026

Case Number: Interim Application No. 1606 of 2026 in Commercial IP Suit No. 679 of 2025

Name of Court: High Court of Judicature at Bombay, Ordinary Original Civil Jurisdiction, Commercial Division

Name of Hon'ble Judge: Justice Sharmila U. Deshmukh

---

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

---

Suggested SEO Titles:

1. Bombay High Court Grants Injunction Against ACIPROX in Pharmaceutical Trademark Dispute

2. Alkem Laboratories v. Numen Pharma: Protection of Medicinal Trademark ALCIPRO Explained

3. Bombay High Court Reiterates Strict Standard for Similar Pharmaceutical Trademarks

4. ALCIPRO vs ACIPROX: Key Takeaways from Bombay High Court's Trademark Judgment

5. Pharmaceutical Trademark Infringement and Passing Off: Analysis of Alkem Laboratories Case

6. Can Prescription Drugs Cause Trademark Confusion? Bombay High Court Answers

7. Anti-Dissection Rule Applied in ALCIPRO vs ACIPROX Trademark Dispute

8. Section 13 of Trade Marks Act and INN Defence Explained Through Alkem v. Numen Pharma

9. Similar Sounding Drug Names and Public Safety: Bombay High Court Judgment Analysis

10. Medicinal Trademark Protection in India: Lessons from Alkem Laboratories v. Numen Pharma

11. Phonetic Similarity in Pharmaceutical Marks: Bombay High Court's Latest Ruling

12. Passing Off and Trademark Infringement in Medicines: ALCIPRO Judgment Explained

---

Suggested SEO Tags:

Alkem Laboratories, Numen Pharma, ALCIPRO trademark, ACIPROX trademark, pharmaceutical trademark dispute, Bombay High Court, medicinal trademark infringement, passing off action, phonetic similarity, anti dissection rule, Cadila Health Care case, Milmet Oftho Industries, Section 13 Trade Marks Act, Section 27 Trade Marks Act, Section 31 Trade Marks Act, Schedule H drugs, trademark injunction, deceptively similar marks, pharmaceutical branding, trademark law India, intellectual property litigation, drug name confusion, medicinal products trademark, goodwill and reputation, common to trade defence, trademark registration, pharmaceutical IP law, Bombay High Court judgment, AdvocateAjayAmitabhSuman, IPAdjutor

---

Headnote of the Judgment:

Alkem Laboratories Ltd., proprietor of the registered trademark "ALCIPRO" since 1990 for pharmaceutical products containing Ciprofloxacin, instituted a suit for infringement and passing off against Numen Pharma Private Limited, which adopted the mark "ACIPROX" in 2023. The defendant contended that "CIPRO" was generic, that the marks were dissimilar, and that the medicines were Schedule H drugs sold only on prescription. The Bombay High Court held that medicinal products require a stricter standard of scrutiny and that even the possibility of confusion must be avoided. Applying the anti-dissection rule and relying upon Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., (2001) 5 SCC 73, and Milmet Oftho Industries v. Allergan Inc., (2004) 12 SCC 624, the Court found "ACIPROX" phonetically similar to "ALCIPRO". It rejected the defendant's reliance on differences in packaging, house marks and prescription-based sale. Holding that the plaintiff had established goodwill and a strong prima facie case of infringement and passing off, the Court granted an interim injunction restraining use of the mark "ACIPROX" and any deceptively similar mark pending disposal of the suit.

====

SC-J.R. Kapoor Vs. Micronix India

Descriptive Prefixes and Trademark Infringement:J.R. Kapoor Vs. Micronix India by Supreme Court

Introduction

The Supreme Court’s decision in J.R. Kapoor v. Micronix India is a significant judgment in Indian trademark law that examines the limits of trademark protection where a disputed word forms part of a descriptive or commonly used expression. The case dealt with a conflict between the trade names “MICRONIX” and “MICROTEL” used in relation to electronic and electrical products. The dispute required the Court to determine whether the use of a common prefix could create a likelihood of confusion sufficient to justify an injunction.

The judgment is important because it highlights a fundamental principle of trademark law: no trader can ordinarily claim monopoly over descriptive or generic words that are commonly associated with a particular technology, product, or industry. At the same time, the Court examined whether the overall trade name, logo, packaging, and visual presentation were sufficiently similar to mislead consumers.

The ruling continues to be relevant for businesses, trademark owners, startups, manufacturers, branding professionals, and intellectual property practitioners. It serves as an important reminder that trademark protection extends to distinctive features of a mark and not necessarily to words that are descriptive of the goods or technology involved. The decision also provides valuable guidance on the principles governing interim injunctions in trademark disputes.

Factual and Procedural Background

The dispute arose between Micronix India, the respondent-plaintiff, and J.R. Kapoor, the appellant-defendant, both of whom were engaged in the manufacture and sale of electrical and electronic products, including cable television equipment, aerial boosters, solid-state boosters, and related apparatus.

Originally, the appellant was one of the partners in a partnership firm known as Micronix India. The firm had been carrying on business since 21 September 1977 and was the proprietor of the registered trademark “MICRONIX” along with a distinctive logo comprising the letters “M” and “T.” The products of the firm were marketed under this trademark and logo.

Subsequently, disputes arose between the partners, resulting in litigation. The partnership was ultimately dissolved pursuant to a consent order dated 14 February 1992 passed in a suit pending before a court in Delhi. Under the terms of the settlement, the trademark “MICRONIX” and the associated logo were allotted to the respondent-plaintiff.

After the dissolution of the partnership, the appellant commenced an independent business manufacturing similar electronic products. In connection with this new venture, the appellant adopted the trade name “MICROTEL” and used a separate logo consisting of the letter “M” designed in a style different from that employed by the respondent. The appellant’s logo appeared in blue colour, while the trade name “MICROTEL” appeared in bold red letters.

Contending that the use of “MICROTEL,” the logo “M,” and the associated cartons infringed its trademark rights and were likely to deceive consumers, the respondent instituted a suit seeking injunction against the appellant. The learned Single Judge granted an interim injunction restraining the appellant from using the impugned trade name, logo, and carton. An appeal against the order was summarily dismissed by a Division Bench of the Delhi High Court. Aggrieved by these orders, the appellant approached the Supreme Court.

The appeal before the Supreme Court was confined to the issue of whether the grant of interim injunction was justified pending final adjudication of the suit.

Dispute Before the Court

The principal question before the Supreme Court was whether the appellant should be restrained, at the interim stage, from using the trade name “MICROTEL,” the logo “M,” and the packaging cartons employed for marketing his products.

The respondent argued that “MICROTEL” was deceptively similar to “MICRONIX” and that both parties were operating in the same field of electronic and electrical goods. It was contended that the use of a similar prefix and logo was likely to mislead consumers into believing that the appellant’s products were associated with the respondent.

The appellant disputed these allegations and argued that the word “micro” was descriptive of micro-chip technology commonly used in electronic products and therefore incapable of exclusive appropriation by any one trader. It was further contended that the suffixes “tel” and “nix” were entirely different, the logos were visually distinct, and the packaging adopted by the parties bore no resemblance sufficient to cause confusion among purchasers.

The Supreme Court was therefore required to determine whether the respondent had established a prima facie case of deceptive similarity warranting continuation of the interim injunction.

Reasoning and Analysis of the Court

The Supreme Court began by emphasizing that at the interim stage the Court was not required to finally determine the rights of the parties. The only issue was whether a temporary restraint should continue pending trial. The Court clarified that its observations would be confined to the interlocutory proceedings and would not prejudice the final adjudication of the suit.

A significant aspect of the Court’s reasoning related to the nature of the word “micro.” The Court observed that both parties were engaged in the manufacture of electronic products in which micro-chip technology played a substantial role. The products included various electronic apparatus, boosters, and equipment where the term “micro” had a direct connection with the technology employed.

The Court held that the word “micro” was descriptive of the technology used in manufacturing many electronic goods and had become a common expression in the industry. Since the word was descriptive and widely used, no trader could claim an exclusive monopoly over it. Any manufacturer producing products involving micro-chip technology would be justified in using the prefix “micro” as part of its trade name.

Having concluded that the prefix “micro” was common and descriptive, the Court proceeded to compare the distinguishing portions of the rival trade names. The Court noted that the suffixes “nix” and “tel” were entirely different both phonetically and visually. According to the Court, the words “MICRONIX” and “MICROTEL” were not likely to create confusion among consumers familiar with electronic goods. The phonetic dissimilarity between “tel” and “nix” was considered significant.

The Court then examined the visual presentation of the trade names. It observed that “MICRONIX” appeared in slim black-and-white letters enclosed within elongated triangular designs, whereas “MICROTEL” appeared in thick bold red letters without any surrounding design. The visual appearance of the two trade names was therefore materially different.

The Court also undertook a comparison of the rival logos. The respondent’s logo consisted of a stylized letter “M” with the letter “T” embedded within it and the word “MICRONIX” appearing below. The entire logo appeared in white against a black square background. In contrast, the appellant’s logo consisted solely of a bold blue letter “M” with distinctive brush-like features and white lines across it. There were no accompanying letters, background designs, or other elements similar to those used by the respondent.

After comparing the logos, the Court concluded that there was no realistic possibility that consumers would be misled into believing that the products originated from the same source. The visual impressions created by the two logos were substantially different.

The Court similarly rejected the respondent’s arguments regarding the packaging cartons. The respondent attempted to point out similarities in addresses, model numbers, and certain descriptive phrases used on the cartons. The Court found these contentions unpersuasive. The Court noted that the respondent’s carton was printed in black and white, whereas the appellant’s carton was in colour and bore a different overall appearance.

Considering the trade names, logos, and cartons as a whole, the Court held that there was not even a remote possibility of confusion or deception among buyers and users of the products. The Court therefore found no justification for continuing the interim injunction.

Final Decision of the Court

The Supreme Court allowed the appeal and set aside the orders of the Single Judge and the Division Bench of the Delhi High Court granting interim injunction against the appellant.

The Court held that the appellant could not be restrained, at the interim stage, from using the trade name “MICROTEL,” the logo “M,” and the associated cartons because the materials on record did not disclose any real likelihood of confusion or deception among consumers.

Point of Law Settled

The judgment establishes that descriptive or generic words commonly associated with a particular technology, trade, or industry cannot ordinarily be monopolized by a single trader.

The decision clarifies that where a common descriptive element forms part of competing trade names, courts must focus on the distinctive portions of the marks while assessing deceptive similarity. The mere presence of a shared descriptive prefix is insufficient to justify an injunction unless the overall trade names, logos, packaging, and commercial impressions are likely to confuse consumers.

The ruling further emphasizes that trademark disputes must be examined from the perspective of ordinary purchasers and that courts should assess phonetic, visual, and structural similarities in their entirety rather than concentrating on isolated common elements.

The judgment remains an important authority on descriptive trademarks, deceptive similarity, common industry expressions, and the grant of interim injunctions in trademark litigation.

Case Details:

Title of the Case: J.R. Kapoor Vs. Micronix India

Date of Judgment/Order: 10 August 1994

Case Number: Civil Appeal No. 2253 of 1994

Citations: 1994 Supp (3) SCC 215; 1994 (14) PTC 260 (SC)

Name of Court: Supreme Court of India

Name of Hon'ble Judge: Justice P.B. Sawant and Justice S.C. Agrawal

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

Disclaimer: Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Suggested SEO Titles:

1. J.R. Kapoor v. Micronix India: Supreme Court on Descriptive Trademarks and Deceptive Similarity

2. Can Anyone Claim Monopoly Over the Word “Micro”? Supreme Court Explains

3. MICRONIX vs MICROTEL: Landmark Trademark Judgment Analysis

4. Supreme Court on Common Descriptive Words in Trademark Law

5. J.R. Kapoor Case Explained: Trade Name Similarity and Consumer Confusion

6. Trademark Protection and Generic Words: Lessons from Micronix India Case

7. Supreme Court Clarifies Limits of Trademark Monopoly in Electronics Industry

8. Descriptive Prefixes and Trademark Infringement: J.R. Kapoor v. Micronix India

9. Interim Injunction in Trademark Disputes: Analysis of the Micronix Case

10. Supreme Court on Phonetic and Visual Comparison of Trademarks

11. Trademark Law and Common Industry Expressions: A Landmark Ruling

12. Understanding Deceptive Similarity Through J.R. Kapoor v. Micronix India

Suggested SEO Tags:

J R Kapoor Case, Micronix India Case, MICROTEL Trademark, MICRONIX Trademark, Descriptive Trademark, Generic Trademark Words, Trademark Infringement India, Deceptive Similarity, Trade Name Dispute, Trademark Litigation India, Supreme Court Trademark Case, Intellectual Property Law India, Trademark Injunction, Common Descriptive Words, Electronic Products Trademark, Trade Dress Comparison, Trademark Monopoly, Trademark Law India, Phonetic Similarity, Visual Similarity Trademark, Interim Injunction IP Law, Electronics Industry Branding, Trademark Case Analysis, Indian Trademark Jurisprudence, Consumer Confusion Test, Trademark Protection India, Passing Off Principles, Brand Identity Dispute, AdvocateAjayAmitabhSuman, IPAdjutor

Headnote of the Judgment:

J.R. Kapoor v. Micronix India, Supreme Court of India, Civil Appeal No. 2253 of 1994, decided on 10.08.1994. The dispute concerned the use of the trade name “MICROTEL” and logo “M” by the appellant after dissolution of a partnership that had previously used the registered trademark “MICRONIX.” The Delhi High Court granted an interim injunction restraining use of the impugned mark, logo, and cartons. Allowing the appeal, the Supreme Court held that the word “micro” was descriptive of micro-chip technology and incapable of exclusive monopoly. The Court found that the trade names “MICRONIX” and “MICROTEL,” their logos, and packaging were visually and phonetically distinct and unlikely to cause confusion among consumers. Consequently, the interim injunction was set aside, leaving the merits of the suit to be determined at trial.

Infographic Thumbnail Prompt:

Create a professional legal YouTube thumbnail in 14:9 ratio, ultra-HD 8K quality. Display two large trademarks “MICRONIX” and “MICROTEL” facing each other with a bold glowing red “VS” in the center. Show electronic products such as TV boosters, circuit boards, microchips, antennas, and electronic equipment in the foreground. Place a large trademark symbol ™ and scales of justice between the competing brands. In the background feature the Supreme Court of India with dramatic courtroom lighting and legal document overlays. Add attention-grabbing headline text: “MICRONIX vs MICROTEL”, “CAN ‘MICRO’ BE MONOPOLIZED?” and “Descriptive Prefixes and Trademark Infringement:J.R. Kapoor Vs. Micronix India by Supreme Court:”. Use professional legal-news graphics, sharp typography, dynamic composition, high contrast colours, and a modern intellectual property law theme suitable for legal education and YouTube publication.Use attached image as Image of lawyer in lawyers dress at left bottom corner  which should cover 20 % of entire image area.

SC-Novartis AG Vs. Union of India

Let me first read the uploaded PDF to get the full details of the case.Now I have enough material from the judgment. Let me compile the comprehensive analytical article.Now I have a comprehensive understanding of the case. Let me write the detailed analytical article.

The Gleevec Verdict: India's Supreme Court Draws the Line Against Evergreening in Novartis AG v. Union of India

---

Introduction

Few patent law judgments anywhere in the world have generated as much attention, debate, and global consequence as the Supreme Court of India's decision in Novartis AG v. Union of India, delivered on April 1, 2013. At its core, this case was about a cancer drug called Gleevec or Glivec, marketed by Novartis AG, a Swiss multinational pharmaceutical giant, and whether the drug's active substance in a particular crystal form deserved a patent in India. But the implications reached far beyond one drug or one company. The judgment went to the very heart of the tension between the rights of patent-holding pharmaceutical corporations and the right of millions of patients in developing countries to access life-saving medicines at affordable prices. It also addressed, for the first time with such depth and clarity by the Supreme Court, the meaning of "evergreening," the controversial practice by which pharmaceutical companies seek to extend their patent monopoly by making minor tweaks to an already known substance and claiming a fresh patent for the slightly modified version. The Court's ruling, written by Justice Aftab Alam (with Justice Ranjana P. Desai concurring), was a resounding rejection of Novartis's patent claim and a definitive statement that Indian patent law, as amended in 2005, imposes a high bar for the patentability of pharmaceutical products, one that is deliberately higher than that set by many Western patent systems.

---

Factual and Procedural Background

The story of this litigation begins with a German scientist named Dr. Jürg Zimmermann, who invented a class of compounds called N-phenyl-2-pyrimidine-amine derivatives. One of these compounds was Imatinib, which was found to have remarkable anti-tumoral properties and became the key ingredient in a drug for the treatment of chronic myeloid leukaemia and certain types of tumours. Dr. Zimmermann filed an application for patent for these compounds in the United States on February 4, 1993, which later became US Patent No. 5,521,184, granted on May 28, 1996. This patent, commonly called the Zimmermann Patent, covered Imatinib and its pharmaceutically acceptable salts, including Imatinib Mesylate, which is the methanesulfonic acid addition salt of Imatinib. After Ciba Geigy merged with Sandoz in 1996, the resulting company became Novartis AG, the appellant in this case.

Gleevec or Glivec, as it is known commercially, is directly derived from the Zimmermann Patent. Novartis has always maintained that Gleevec is fully covered by Zimmermann Patent No. 5,521,184. In the United States, Novartis sought and obtained extension of the Zimmermann Patent's term for the period of regulatory review for Gleevec. When a US company called NATCO sought to market its drug Veenat 100 (containing Imatinib Mesylate as its active ingredient) in the United Kingdom, Novartis successfully stopped it on the basis of the Zimmermann Patent. Before filing its Indian patent application, Novartis made an application in 2002 for the grant of Exclusive Marketing Rights (EMR) for the subject product under Section 24-A (since omitted) of the Patents Act, 1970. The Patent Office granted EMR to the appellant in 2003.

Now comes the critical point of the case. Novartis AG filed an application on July 17, 1998, before the Indian Office of Controller of Patents and Designs, for grant of a patent not for Imatinib or Imatinib Mesylate (the known salt), but specifically for the beta-crystalline form of Imatinib Mesylate, which Novartis referred to as beta-IM or β-IM. The priority date claimed was July 18, 1997, being the date on which the patent was applied for in Switzerland. The Indian Patent Office put the application on hold by adopting the mailbox procedure on account of expected changes in the patent regime in India. It was only after the Patents Act, 1970, was amended in 2005, that the application was taken up for consideration.

On January 25, 2006, the Assistant Controller of Patents vide five separate orders rejected the appellant's patent claim for β-IM, holding that the invention claimed by the appellant was anticipated by prior publication, specifically by Zimmermann Patent No. 5,521,184, and that the same was obvious to a person skilled in the art in view of the disclosures provided in Zimmermann Patent No. 5,521,184 specifications. The Assistant Controller further held that the patentability of the alleged invention was disallowed by Section 3(d) of the Patents Act as amended.

Aggrieved, Novartis appealed to the Intellectual Property Appellate Board (IPAB). By its order dated June 26, 2009, the IPAB held that although β-IM satisfied the test of invention/inventive step prescribed in Sections 2(1)(j) and (ja) of the Patents Act, 1970, it failed the test of enhanced efficacy prescribed in Section 3(d) thereof. The IPAB dismissed the appeals filed by the appellant on this ground. However, in a partial relief to Novartis, the IPAB held that the appellant could not be denied a process patent for the preparation of β-IM. The appellant challenged the IPAB order before the Supreme Court of India directly under Article 136 of the Constitution. The parties who had opposed the patent claim before the authorities below, including Cipla Ltd., NATCO Pharma Limited, the Cancer Patients Aid Association, and others, were permitted to file SLPs in the Supreme Court against the partial ruling in favour of the appellant regarding the process patent. Thus, all parts of the IPAB order were appealed against, and all issues were open for determination by the Supreme Court. The Civil Appeals before the Supreme Court were Civil Appeals Nos. 2706-716 of 2013 (with Civil Appeal No. 2728 of 2013 and Civil Appeals Nos. 2717-27 of 2013).

---

The Dispute

Before the Supreme Court, the central question was deceptively simple but deeply consequential: could Novartis AG obtain an Indian patent for the beta-crystalline form of Imatinib Mesylate (β-IM), which it marketed as Gleevec/Glivec for the treatment of chronic myeloid leukaemia? This question broke down into several layered issues.

The first was whether β-IM was a new substance altogether, or merely a new form of an already known substance. This was crucial because Section 3(d) of the Patents Act, 1970, as amended in 2005, specifically deals with the situation where a new form of a known substance is claimed for patent, and imposes a requirement that the new form must show significantly enhanced efficacy compared to the known substance.

The second was what the correct legal test for "invention" was under Indian law, specifically under Sections 2(1)(j) and 2(1)(ja) of the Patents Act, 1970. Did β-IM satisfy this test?

The third, and perhaps the most intensely debated, question was the meaning, scope, and applicability of Section 3(d) of the Patents Act, 1970, as amended by the Patents (Amendment) Act, 2005. Novartis strenuously argued that Section 3(d) was an exception provision, operating only in the manner of a caution or as an "ex majore cautela" clause, and that if an applicant passed the test of invention under Sections 2(1)(j) and (ja), it could not be denied a patent merely on the basis of Section 3(d). The respondents argued the opposite: that Section 3(d) represented an independent and additional tier of requirement for chemical substances and pharmaceuticals, deliberately designed to prevent evergreening.

The fourth question was what "efficacy" meant under Section 3(d) and its Explanation. Novartis argued that β-IM had enhanced bioavailability (it was 30% more bioavailable than Imatinib in free base form), and that bioavailability was a form of efficacy. The respondents argued that "efficacy" in the context of a medicine must mean therapeutic efficacy, that is, the ability to cure or treat the disease for which the medicine is prescribed, and that mere physicochemical properties or enhanced bioavailability did not constitute enhanced therapeutic efficacy.

Novartis submitted before the Supreme Court through its Senior Advocate Mr. Gopal Subramanium that both Imatinib Mesylate and β-IM were new products produced as a result of two inventions; that beginning from Imatinib-in-free-base-form, in a two-stage invention they first produced Imatinib Mesylate and then developed β-IM; that Zimmermann Patent No. 5,521,184 did not teach a person how to prepare Imatinib Mesylate from Imatinib-in-free-base; and that Section 3(d) operated only ex majore cautela and was not meant to be an exception to the test of invention. The respondents, including Cipla Ltd. through Senior Advocate Mr. Harish Salve and Mr. Harish Salve and Ranbaxy through Ms. Prathiba Singh, strongly opposed all these positions.

---

Reasoning and Analysis of the Court

The Supreme Court's judgment, authored by Justice Aftab Alam (Justice Ranjana P. Desai concurring), is a masterly piece of legal analysis that combines an examination of the statutory provisions, their legislative history, the parliamentary debates, international treaty obligations, and the specific facts of the case.

The Court began by setting out the framework of the Patents Act, 1970, noting that "invention" and "patentability" are two distinctly separate concepts under Indian law. Section 2(1)(j), which defines "invention," requires a new product or process involving an inventive step that is capable of industrial application. Section 2(1)(ja) defines "inventive step" as a feature of an invention that involves technical advance as compared to existing knowledge or economic significance, or both, and that makes the invention not obvious to a person skilled in the art. Section 2(1)(ac) defines "capable of industrial application" as a product that is capable of being made or used in an industry. Together, these provisions mean that to qualify as an invention under Indian law, a product must be new (not anticipated), must involve an inventive step (not obvious), and must be capable of industrial application. The Court emphasized that something may be an "invention" in the general sense and yet may not qualify as a patentable invention under the 1970 Act, and something may even satisfy the definition of "invention" under the 1970 Act and yet be denied a patent for other larger considerations, as stipulated in Section 3 of the Act.

Section 3 of the Patents Act lists things that "are not inventions within the meaning of this Act." Section 3(d), as amended in 2005, is the provision that became the epicenter of this litigation. It states that the following shall not be deemed to be an invention: "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant." The Explanation to Section 3(d) is equally significant: "For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy."

The Court then undertook a detailed examination of the legislative history and parliamentary debates around the 2005 amendment to determine the precise intent of Section 3(d). The Court found that India had an absolutely unenviable task in amending the Patents Act, 1970, to make it TRIPS-compliant without compromising on public health considerations. The TRIPS Agreement had aroused grave concerns about its impact on public health, particularly the inverse relationship between product patents in pharmaceuticals and the availability of essential medicines at affordable prices. The Court noted that India had, after the patent system in India barred the grant of patents for pharmaceutical and chemical substances, developed a pharmaceutical industry that became a major supplier of drugs at cheap prices to a number of developing and underdeveloped countries. Ninety per cent of the drugs India had been supplying to sub-Saharan Africa for treating AIDS were generic drugs whose prices had dramatically fallen because of the competition. The reintroduction of product patents in the Indian patent system through the TRIPS Agreement became a cause of alarm, particularly from the standpoint of public health and the supply of medicines to poor countries.

In Parliament, the government introduced Section 3(d) as the specific provision that would prevent the abuse of product patents in pharmaceutical substances and check the practice of evergreening. In fact, the Court noted that the whole Parliamentary debate on the Patents Amendment Bill centred on medicines and drugs, with about 80% of the debate focusing on medicines and drugs and the remaining 20% on agricultural chemicals. The Court held that the amended portion of Section 3(d) of the 1970 Act sets up a second tier of qualifying standards for chemical substances and pharmaceutical products in order to leave the door open for true and genuine inventions but, at the same time, to check any attempt at repetitive patenting or extension of the patent term on spurious grounds.

On the question of whether Section 3(d) was an ex majore cautela clause or an independent substantive provision, the Court firmly rejected Novartis's argument. The Court held that Section 3(d) is not a provision ex majore cautela and is applicable to the subject product β-IM. The submission of Novartis that Section 3(d) has no application to the subject product because it has satisfied the tests of invention as provided in Sections 2(1)(j) and (ja) was completely misconceived, for the reason that Section 3 was designed to defeat an application for patent which passed through the definition of invention. Section 3 was not a mere cautionary provision; it was a substantive disqualifying provision. If clause (d) is isolated from the rest of Section 3, and the legislative history behind the incorporation of Chapter II in the Patents Act, 1970, is disregarded, then it may be possible to see Section 3(d) as an extension of the definition of "invention" and to link Section 3(d) with Sections 2(1)(j) and (ja). In that case, on reading Sections 2(1)(j) and (ja) with Section 3(d), it would appear that the 1970 Act sets different standards for qualifying as "inventions" — for medicines and drugs and other chemical substances, the 1970 Act sets the invention threshold further higher, by virtue of the amendments made in Section 3(d) in the year 2005.

Next, the Court turned to the specific facts to determine whether β-IM was covered by Zimmermann Patent No. 5,521,184. Novartis had argued that Zimmermann Patent No. 5,521,184 did not teach how to prepare Imatinib Mesylate from Imatinib free base. The Court examined the Zimmermann Patent in painstaking detail, noting that the patent related to N-phenyl-2-pyrimidine-amine derivatives, that Example 21 in the patent exemplified Imatinib (referred to as CGP 57148), and that Claim 23 listed Imatinib along with its pharmaceutically acceptable salts. A key article from the journal Cancer Research, published in January 1996, further showed that even before the Indian patent application, there was a detailed discussion about the anti-tumoral properties of Imatinib and its methanesulfonate salt (i.e., Imatinib Mesylate), with CGP 57148B referring specifically to Imatinib Mesylate. Critically, the US Board of Patent Appeals, in the case of the appellant itself, when granting US Patent Zimmermann Patent No. 6,894,051 B1 for β-IM, had proceeded on the basis that Zimmermann Patent No. 5,521,184 had the teaching for making of Imatinib Mesylate from Imatinib for any person skilled in the art. The Court noted the deeply ironic position Novartis found itself in: in the United States it had always maintained that Gleevec was part of Zimmermann Patent No. 5,521,184, used that position to extend the patent term, and relied on the Zimmermann Patent to stop NATCO from marketing its generic drug in the UK. But before the Indian authorities, it was now claiming that Imatinib Mesylate was not taught by or covered by the Zimmermann Patent. The Court held that Novartis was bound by the finding recorded in its own case in the United States. Accordingly, "Imatinib Mesylate" was a known substance under Zimmermann Patent No. 5,521,184. Therefore, β-IM was a new form of a known substance, and Section 3(d) was directly applicable.

On the question of what "efficacy" means for the purposes of Section 3(d) of the Patents Act as applied to medicines, the Court adopted a strict and narrow interpretation. The Court referred to the New Oxford Dictionary of English (1998 Edition) which defines "efficacy" as "the ability to produce a desired or intended result." The Court held that the test of efficacy in each case would depend upon the function, utility or purpose of the product under consideration. In the case of a medicine, the efficacy must be its therapeutic efficacy — its ability to produce the desired therapeutic result, meaning to cure or treat the disease for which it is prescribed. The Court held that mere improvement in physicochemical properties like better flow, thermodynamic stability, lower hygroscopicity, and enhanced bioavailability do not automatically lead to an inference of better therapeutic efficacy. It was absolutely clear, the Court stated, that the physico-chemical properties of β-IM, namely more beneficial flow properties, better thermodynamic stability, and lower hygroscopicity, had nothing to do with therapeutic efficacy. On bioavailability, the Court noted that Novartis claimed that β-IM had 30% increased bioavailability compared to Imatinib in free base form. However, even accepting this claim, the Court reasoned that bioavailability by itself may not necessarily lead to enhanced therapeutic efficacy. The Court relied on a medical commentary which stated that bioavailability studies are meant to determine the rate and extent of absorption of a drug substance; if a drug product is not bioavailable, it cannot be regarded as effective, but a determination that a drug product is bioavailable is not in itself a determination of effectiveness. The Court further noted that the enhanced therapeutic efficacy of β-IM over Imatinib Mesylate had to be specifically claimed and established by research and empirical data, and this had not been done. Indeed, the Court pointed to the clear and unambiguous averments in the subject Indian patent application, in which all the references were to Imatinib in free base form (or to the alpha crystalline form of Imatinib Mesylate in respect of flow properties, thermodynamic stability, and lower hygroscopicity), but there was no claim of any therapeutic advantage for β-IM over Imatinib Mesylate itself.

The Court also addressed an important factual point regarding the drug Gleevec as actually marketed in India (and also in the United States). Gleevec/Glivec was described on its package as "Imatinib Mesylate tablets 100 mg" with no reference to β-IM at all. This meant that the claim for a patent for β-IM was actually an attempt to obtain a patent for "Imatinib Mesylate," which would otherwise be impermissible given the Zimmermann Patent's coverage. The Court found this an attempt to obtain patent for "Imatinib Mesylate" which would otherwise be impermissible.

The Court also addressed the broader principle of patent coverage versus patent disclosure. Indian patent law, the Court held, does not permit the scope of patent coverage or claims to be wider than the disclosures or teachings contained in the patent. A limited monopoly is granted to the patentee in return for making his knowledge available to the public domain. Patent coverage or claim cannot be wider than the disclosures and teachings contained in the patent. This was significant because Novartis, in claiming that its Indian patent application covered a new and separate product from the Zimmermann Patent, was effectively trying to claim protection beyond what it had disclosed.

The Court also rejected Novartis's argument that Indian patent law should be aligned with the standard of a "manipulative step" used in United States patent law. In the United States, when the US Board of Patent Appeals granted β-IM a patent, it recognized it as involving a "manipulative step" which may not necessarily involve an "inventive step." The Court held that the standard under Indian law is "inventive step," not "manipulative step," and the two are clearly different things. The requirement of "inventive step" under Indian law is a higher standard than the "manipulative step" recognized in the US context. Indian patent law, the Court stated, lays down a high requirement of "inventive step" in Section 2(1)(ja) and "enhanced efficacy" in Section 3(d) for incremental improvements of known substances or processes to qualify for patent protection. Standard of inventiveness is high under Indian patent law, and patent law in India should not develop in a manner where the scope of patent is determined based not on the intrinsic worth of the invention but by artful drafting of its claims by skilful lawyers, where patents are traded as a commodity not for production and marketing of patented products but to search for someone who may be sued for infringement.

---

Final Decision of the Court

The Supreme Court dismissed the appeals filed by Novartis AG with costs. It held that the subject product, β-crystalline-Imatinib Mesylate (β-IM), failed both the test of invention under Sections 2(1)(j) and (ja) of the Patents Act, 1970, and the test of enhanced efficacy/patentability as laid down under Section 3(d) read with its Explanation. The Court therefore held that β-IM was not entitled to the grant of an Indian patent. The Court further dismissed the cross-appeals of the other parties (Cipla, NATCO, Cancer Patients Aid Association, and others) against the partial relief granted by the IPAB in favour of Novartis regarding the process patent, holding that the question of a process patent for β-IM was not strictly a part of the subject matter before the Court.

---

Points of Law Settled in the Case

This judgment settled several vital and enduring principles of Indian patent law, particularly in relation to pharmaceutical products.

The most foundational principle established is that "invention" and "patentability" are two distinctly separate and cumulative concepts under the Patents Act, 1970. A substance may satisfy the definition of "invention" under Sections 2(1)(j) and (ja) and yet be denied a patent if it fails the requirements of Section 3(d). Section 3(d) is not an ex majore cautela provision; it is a substantive, independent tier of qualifying standards specifically for chemical substances and pharmaceuticals.

The Court definitively interpreted the meaning of "efficacy" under Section 3(d) and its Explanation for the purpose of pharmaceutical products: efficacy means therapeutic efficacy, that is, the ability of the medicine to produce its desired therapeutic result in treating the disease for which it is prescribed. Mere improvements in physicochemical properties such as better flow, greater stability, lower hygroscopicity, or improved bioavailability do not by themselves constitute enhanced therapeutic efficacy unless it is specifically established with research and empirical data that the enhanced physicochemical property or bioavailability actually translates into enhanced therapeutic effect.

The Court established that a new pharmaceutical product in the context of Section 3(d) and its Explanation must not mean something entirely new or unfamiliar; it may mean something "different from a recent previous" product or a product "regarded as better than what went before" or a product "in addition to another or others of the same kind." Such new pharmaceutical products, however, must additionally pass the test of enhanced efficacy to qualify for patent protection.

The Court held that the standard of inventiveness under Indian patent law is high, deliberately set to require a genuine technical advance and not merely a manipulative step, in contrast to the US standard. This means that incremental improvements of known pharmaceutical substances or processes, unless they genuinely advance the state of the art in a way that is not obvious to a person skilled in the art and demonstrate enhanced efficacy, will not qualify for patent protection in India.

The Court settled the principle that the scope of a patent claim cannot be wider than the disclosure or teaching contained in the patent. The patentee's monopoly is limited to what has been disclosed in the patent specification. This prevents companies from using artful claim drafting to secure broader protection than they have actually invented and disclosed.

The Court also settled the principle that an applicant for a patent is bound by positions taken and findings recorded in patent proceedings in other jurisdictions, particularly when the applicant itself has relied on those findings. Novartis, having always maintained in the United States and elsewhere that Gleevec was part of the Zimmermann Patent, could not turn around and claim before Indian authorities that Imatinib Mesylate was not disclosed in the Zimmermann Patent.

---

Case Details

Title: Novartis AG v. Union of India and Others

Date of Order: April 1, 2013

Case Numbers: Civil Appeals Nos. 2706-716 of 2013 (with Civil Appeal No. 2728 of 2013 and Civil Appeals Nos. 2717-27 of 2013)

Citation: (2013) 6 SCC 1

Name of Court: Supreme Court of India

Hon'ble Judges: Aftab Alam, J. and Ranjana P. Desai, J.

---

Disclaimer: Readers are advised not to treat this as a substitute for legal advice as it may contain errors in perception, interpretation, and presentation.

Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi

---

Suggested SEO Titles

1. Novartis AG Vs. Union of India: The Landmark Supreme Court Ruling That Blocked Gleevec's Indian Patent
2. Section 3(d) of the Indian Patents Act Explained: The Novartis Gleevec Judgment and Evergreening
3. India's Supreme Court on Pharmaceutical Patent Evergreening: Novartis Case Analysis 2013
4. Therapeutic Efficacy vs. Bioavailability in Indian Patent Law: Lessons from the Novartis Judgment
5. Imatinib Mesylate Patent Denied in India: Complete Legal Analysis of the Novartis Decision
6. TRIPS, Access to Medicines, and Indian Patent Law: The Novartis Gleevec Case Fully Explained
7. What Is Evergreening in Patent Law? India's Supreme Court Answers in Novartis v. Union of India
8. Section 3(d) Patents Act 1970: How India Protects Generic Drug Access — The Novartis Case

---

SEO Tags

Novartis AG v Union of India, Gleevec patent India, Section 3d Patents Act 1970, Imatinib Mesylate patent, evergreening patent India, pharmaceutical patent India, beta crystalline Imatinib Mesylate, therapeutic efficacy patent law India, TRIPS Agreement India pharmaceutical, Indian patent law 2005 amendment, Supreme Court patent 2013, generic medicines India patent, IPAB India patent, bioavailability therapeutic efficacy distinction, inventive step India patent, Cancer Patients Aid Association patent case, Cipla Ranbaxy Novartis patent, access to medicines India, Zimmermann Patent 5521184, Patents Amendment Act 2005 India, 2013 6 SCC 1, Aftab Alam judgment patent, Ranjana Desai Supreme Court patent, pharmaceutical product patent India, known substance new form patent, AdvocateAjayAmitabhSuman, IPAdjutor

---

Headnote

Under the Patents Act, 1970, "invention" and "patentability" are two distinct and cumulative concepts. For a pharmaceutical or chemical substance that is a new form of a known substance, the applicant must satisfy not only the test of "invention" as defined in Sections 2(1)(j) and (ja) but also the separate and independent test of enhanced efficacy prescribed in Section 3(d) read with its Explanation. Section 3(d) is a substantive disqualifying provision and not an ex majore cautela clause. For the purposes of Section 3(d) of the Patents Act, 1970, and its Explanation, "efficacy" in the case of a medicine means therapeutic efficacy — the ability of the medicine to cure or treat the disease for which it is prescribed. Mere improvement in physico-chemical properties such as better flow, thermodynamic stability, lower hygroscopicity, or enhanced bioavailability does not constitute enhancement of known efficacy unless specifically established with research and empirical data to result in enhanced therapeutic effect. Beta-crystalline Imatinib Mesylate (β-IM), the active ingredient of the cancer drug Gleevec/Glivec, being a new form of Imatinib Mesylate, which was itself a known substance disclosed in Zimmermann Patent No. 5,521,184, failed both the test of invention and the test of enhanced efficacy, and was accordingly held not entitled to an Indian patent. The standard of inventiveness under Indian patent law is deliberately high and differs from the standard of a "manipulative step" recognized in United States patent law. Indian patent law disallows evergreening and sets up a second tier of qualifying standards for pharmaceutical products to permit genuine inventions while preventing repetitive patenting or extension of patent term on spurious grounds.